Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trialSéverine Vermeire, Walter Reinisch, William J. Sandborn et al.|The Lancet|2017Cited by 198
Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT IIWalter Reinisch, Séverine Vermeire, Silvio Danese et al.|Journal of Crohn s and Colitis|2021Cited by 34
901a A Randomized, Multicenter Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Anti-MAdCAM Antibody PF-00547659 (PF) in Patients With Moderate to Severe Ulcerative Colitis: Results of the TURANDOT StudyWalter Reinisch, Séverine Vermeire, William J. Sandborn et al.|Gastroenterology|2015Cited by 26
P036 LONG-TERM SAFETY AND EFFICACY OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) ANTIBODY SHP647 IN ULCERATIVE COLITIS: AN OPEN-LABEL EXTENSION STUDY (TURANDOT II)Walter Reinisch, Séverine Vermeire, William J. Sandborn et al.|Inflammatory Bowel Diseases|2019Cited by 4
Tu1737 – Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (MADCAM-1) Antibody Shp647 in Ulcerative Colitis: Results from the Open-Label Extension Study Turandot IiWalter Reinisch, Séverine Vermeire, William J. Sandborn et al.|Gastroenterology|2019Cited by 1